|
|
|
15.04.26 - 11:00
|
RemeGen Receives USD650M Upfront Payment from AbbVie for RC148 (AAStocks)
|
|
|
RemeGen (09995.HK) announced that it has received an upfront payment of USD650 million from AbbVie (through its holding company) under an exclusive licensing agreement for RC148, a novel PD-1/VEGF bispecific antibody independently developed by the company. The collaboration between the two parties is currently progressing smooth......
|
|
|
01.04.26 - 17:45
|
Remegen RC288 for Injection Clinical Trial Approved (AAStocks)
|
|
|
Remegen (09995.HK) announced that the Phase I/IIa clinical trial of RC288 (drug name: RC288 for Injection), a bispecific antibody-drug conjugate (ADC) independently developed by the company, has been approved by the National Medical Products Administration. The trial evaluates RC288 as a monotherapy for the treatment of locally ......
|
|
|
31.03.26 - 21:00
|
Results: RemeGen Narrows Full-Year Loss to RMB77.08 Million (AAStocks)
|
|
|
RemeGen-B (02297.HK) announced its 2025 annual results, reporting revenue of RMB19.18 million, a year-on-year decrease of 51.8%. The loss narrowed from RMB113 million in the previous year to RMB77.08 million, with a loss per share of RMB0.06. No final dividend was declared. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
|
|
25.03.26 - 19:45
|
Results: RemeGen Full-Year Loss Expands to RMB278 Million (AAStocks)
|
|
|
RemeGen-B (06938.HK) announced its 2025 annual results, with revenue recorded at RMB149 million, representing a year-on-year increase of 4.1%. The loss expanded from RMB270 million in the previous year to RMB278 million, with a loss per share of RMB2.11. No dividend will be distributed. (de/d)~AASTOCKS Financial NewsWebsite: www......
|
|
|
05.02.26 - 05:45
|
Research: Citi Re-rates REMEGEN at Buy/ High Risk w/ TP $105 (AAStocks)
|
|
|
Citi Research issued a research report renewing rating at Buy/High Risk on REMEGEN (09995.HK) after a period of Rating Suspended, with a target price of $105, as the Group's collaboration with AbbVie on the PD-1/VEGF candidate RC148, which further expanded the global potential of its pipeline candidates.The broker believed t......
|
|
|
|
|
|
|
13.01.26 - 03:15
|
REMEGEN Once Spikes 14%+ After Granting AbbVie Exclusive License for RC148 (AAStocks)
|
|
|
REMEGEN (09995.HK) opened 8.8% higher at $101 today (13th), and once spiked 14.9% to a high of $106.6 in the morning session. It last printed at $101.2, rallying 9.05%, with a trading volume of 7.2058 million shares, involving $740 million.REMEGEN entered into an exclusive licensing agreement with AbbVie, under which AbbVie will......
|
|
|
|
|
|
|
|
|
|
|
17.10.25 - 14:03
|
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology′s Kidney Week 2025 (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored by Vor Bio's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), which evaluated telitacicept in adults with IgA neuropathy (IgAN), will be presented as a late-breaking oral presentation at American Society of Nephrology's (ASN) Kidney Week 2025 being held Nov 5-9, 2025, in Houston, Texas....
|
|
|
|
|
29.09.25 - 13:03
|
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren′s Disease Clinical Study at ACR Convergence 2025 (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren's disease, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois....
|
|
|
|
|
|
|
17.09.25 - 22:18
|
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, being held October 29 to November 1, 2025, at the Hilton San Francisco Union Square in San Francisco, California....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
